scholarly journals The effects of high-dose calcitriol and individualized exercise on bone metabolism in breast cancer survivors on hormonal therapy: a phase II feasibility trial

2018 ◽  
Vol 26 (8) ◽  
pp. 2675-2683 ◽  
Author(s):  
Luke J. Peppone ◽  
Marilyn Ling ◽  
Alissa J. Huston ◽  
Mary E. Reid ◽  
Michelle C. Janelsins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Bone Metabolism ◽  
Phase Ii ◽  
Hormonal Therapy ◽  
Breast Cancer Survivors ◽  
Feasibility Trial ◽  
High Dose

scholarly journals Effects of a Structured Weight-Bearing Exercise Program on Bone Metabolism Among Breast Cancer Survivors: A Feasibility Trial

2010 ◽  
Vol 10 (3) ◽  
pp. 224-229 ◽  
Author(s):  
Luke J. Peppone ◽  
Karen M. Mustian ◽  
Michelle C. Janelsins ◽  
Oxana G. Palesh ◽  
Randy N. Rosier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Bone Metabolism ◽  
Breast Cancer Survivors ◽  
Weight Bearing ◽  
Exercise Program ◽  
Feasibility Trial

The CAROLE (CArdiac Related Oncologic Late Effects) Study: A Phase II, single-arm feasibility trial.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 11569-11569 ◽  
Author(s):  
Lindsay Puckett ◽  
Shahryar Saba ◽  
Sonia Henry ◽  
Stacey Rosen ◽  
Elise Rooney ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Phase Ii ◽  
Late Effects ◽  
Breast Cancer Survivors ◽  
Feasibility Trial ◽  
Cardiac Screening ◽  
Long Term Survivors ◽  
Clinical Trial Information

11569 Background: Long-term breast cancer survivors are at risk of late effects from cardiotoxic (tox) radiation (RT) and chemotherapy (chemo). However, there is a paucity of data to recommend appropriate cardiac screening for those ~10 years (yrs) after diagnosis (dx). This phase II, single arm study assessed multimodality screening in a heterogeneous cohort of long-term survivors. Methods: Our prospective, single center pilot study enrolled 201 (of 200 planned) eligible patients (pts): age 18-65 at dx, with treatment (tx) for breast cancer (any stage/tx) in 2004-2011 (≥6 yrs prior), with no cardiac disease (dz) at dx. The primary endpoint was presence of any cardiac dz (preclinical or clinical) on electrocardiogram (EKG), echocardiogram (echo), or coronary artery calcium CT (CAC CT); secondary endpoint included clinical (clin) dz alone. Subgroups assessed were: no tox chemo or RT (no tox), tox RT (left-sided) alone, tox chemo (anthracycline) alone, and both tox chemo and tox RT (tox chemoRT). Results: After enrollment (6/2017-7/2018), 200 pts had sufficient data for analysis. Median age was 50 (29-65) at dx, 63 (37-77) at imaging, and interval (dx to imaging) was 11.5 (6.7-14.5) yrs. There were 44% no tox, 31.5% tox RT, 16% tox chemo, and 8.5% tox chemoRT pts. Among all pts, 77.6% displayed evidence of any cardiac dz, 51.5% had clin dz. Per modality, rates of any and clin dz were: 27.1%/10% EKG, 50.0%/25.3% echo, and 50.8%/45.8% CAC CT. Among subgroups, these rates were: 73.9%/53.4% no tox, 82.5%/58% tox RT, 75%/38.7% tox chemo, and 82.4%/35.3% tox chemoRT (NS on χ2 test, p = .58/p = .15). Multivariable logistic regression with tox RT, tox chemo, and age as covariates, showed no significant tox RT (NS) or tox chemo effect (NS), however, increasing age was significantly associated with higher incidence of cardiac dz (p < 0.01; OR = 1.12 per yr, 95% CI: 1.07-1.18). Conclusions: Among pts with a median of > 10 yrs post breast cancer tx, multimodality CAROLE screening was feasible and showed high rates of cardiac dz (any/clin = 77.6%/51.5%) among all subgroups, including those without tox tx. This study provides evidence for long-term cardiac screening in a diverse group of breast cancer survivors and provides a novel pathway for evaluation. Clinical trial information: NCT03235427.

scholarly journals Perilla Oil and Bifidobacterium for Alleviating Fear of Cancer Recurrence in Breast Cancer Survivors: Study Protocol for a Three-Arm Phase II Randomized Controlled Study (POB Study)

2021 ◽  
Vol 4 (3) ◽  
pp. 46
Author(s):  
Yohei Sasaki ◽  
Mina Honyashiki ◽  
Takayuki Kinoshita ◽  
Akira Matsui ◽  
Ayako Nakashoji ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Phase Ii ◽  
Study Protocol ◽  
Breast Cancer Survivors ◽  
Cancer Recurrence ◽  
Fear Of Cancer Recurrence ◽  
Randomized Controlled ◽  
Perilla Oil ◽  
Fear Of Cancer

The fear of cancer recurrence (FCR) is the most common and most severe unmet need among cancer survivors. Safe treatments for the FCR that are easily disseminated are greatly needed. Our primary aim is a preliminary evaluation of the efficacy and effect size of perilla oil, which is rich in omega-3 fatty acids, and Bifidobacterium, a probiotic, on FCR in breast cancer survivors after the completion of chemotherapy. This study has been planned as an exploratory clinical study (phase II) and will be conducted as a three-arm, 12-week parallel group, masked-rater randomized controlled trial. Fifteen participants will be randomized with 1:1:1 allocation to receive Bifidobacterium plus perilla oil, Bifidobacterium alone, or no intervention (control). Interventions will end within 12 weeks after the random allocation of each participant. The participants will be outpatients with invasive breast cancer aged 20 years or older whose chemotherapy was completed at least 6 months before registration; hormone therapy may be ongoing. The primary outcome will be severity of FCR at 12 weeks assessed by masked raters using the 4-item Concerns about Recurrence Scale concerning overall fear of recurrence. The study protocol for the current study is registered in the Japan Registry of Clinical Trials (jRCTs031200029).

scholarly journals Providers’ perspectives on adherence to hormonal therapy in breast cancer survivors. Is there a role for the digital health feedback system?

2018 ◽  
Vol 9 (2) ◽  
pp. 175-184 ◽  
Author(s):  
Alejandra Hurtado-de-Mendoza ◽  
Mark L. Cabling ◽  
Asma Dilawari ◽  
Jeanine Warisse Turner ◽  
Nicole C. Fernández ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Hormonal Therapy ◽  
Breast Cancer Survivors ◽  
Digital Health ◽  
Feedback System

scholarly journals Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review

2012 ◽  
Vol 134 (2) ◽  
pp. 459-478 ◽  
Author(s):  
Caitlin C. Murphy ◽  
L. Kay Bartholomew ◽  
Melissa Y. Carpentier ◽  
Shirley M. Bluethmann ◽  
Sally W. Vernon
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Clinical Practice ◽  
Cancer Survivors ◽  
Hormonal Therapy ◽  
Breast Cancer Survivors ◽  
Adjuvant Hormonal Therapy

A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes

2018 ◽  
pp. 1-11 ◽  
Author(s):  
Renee Stubbins ◽  
Tiancheng He ◽  
Xiaohui Yu ◽  
Mamta Puppala ◽  
Chika F. Ezeana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Health Care ◽  
Cancer Survivors ◽  
Behavior Modification ◽  
Technology Use ◽  
Breast Cancer Survivors ◽  
Health Care Team ◽  
Care Team ◽  
Feasibility Trial ◽  
System Usability Scale

Purpose Only 34% of breast cancer survivors engage in the recommended level of physical activity because of a lack of accountability and motivation. Methodist Hospital Cancer Health Application (MOCHA) is a smartphone tool created specifically for self-reinforcement for patients with cancer through the daily accounting of activity and nutrition and direct interaction with clinical dietitians. We hypothesize that use of MOCHA will improve the accountability of breast cancer survivors and help them reach their personalized goals. Patients and Methods Women with stages I to III breast cancer who were at least 6 months post–active treatment with a body mass index (BMI) greater than 25 kg/m2 were enrolled in a 4-week feasibility trial. The primary objective was to demonstrate adherence during weeks 2 and 3 of the 4-week study period (14 days total). The secondary objective was to determine the usability of MOCHA according to the system usability scale. The exploratory objective was to determine weight loss and dietitian-participant interaction. Results We enrolled 33 breast cancer survivors who had an average BMI of 31.6 kg/m2. Twenty-five survivors completed the study, and the average number of daily uses was approximately 3.5 (range, 0 to 12) times/day; participants lost an average of 2 lbs (+4 lbs to −10.6 lbs). The average score of usability (the second objective) was 77.4, which was greater than the acceptable level. More than 90% of patients found MOCHA easy to navigate, and 84% were motivated to use MOCHA daily. Conclusion This study emphasizes the importance of technology use to improve goal adherence for patients by providing real-time feedback and accountability with the health care team. MOCHA focuses on the engagement of the health care team and is integrated into clinical workflow. Future directions will use MOCHA in a long-term behavior modification study.

scholarly journals A randomized phase II trial of MOVING ON: An intervention to increase exercise outcome expectations among breast cancer survivors

2018 ◽  
Vol 27 (10) ◽  
pp. 2450-2457 ◽  
Author(s):  
Rachel Hirschey ◽  
Gretchen Kimmick ◽  
Marilyn Hockenberry ◽  
Ryan Shaw ◽  
Wei Pan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Phase Ii ◽  
Breast Cancer Survivors ◽  
Phase Ii Trial ◽  
Outcome Expectations ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document